Cancer Drug Firm Duped Investors In $26M Offering: Suit
Biopharmaceutical company GenVec Inc. raised $26.2 million from shareholders to develop a pancreatic cancer treatment it knew to be ineffective, according to a putative class action suit filed Friday in Maryland...To view the full article, register now.
Already a subscriber? Click here to view full article